IL322257A - שיטות לטיפול בסרטן השד - Google Patents
שיטות לטיפול בסרטן השדInfo
- Publication number
- IL322257A IL322257A IL322257A IL32225725A IL322257A IL 322257 A IL322257 A IL 322257A IL 322257 A IL322257 A IL 322257A IL 32225725 A IL32225725 A IL 32225725A IL 322257 A IL322257 A IL 322257A
- Authority
- IL
- Israel
- Prior art keywords
- dose
- neob
- administered
- treatment
- ribociclib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363486496P | 2023-02-23 | 2023-02-23 | |
| US202463625371P | 2024-01-26 | 2024-01-26 | |
| PCT/IB2024/051682 WO2024176147A1 (en) | 2023-02-23 | 2024-02-21 | Methods for treating breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL322257A true IL322257A (he) | 2025-09-01 |
Family
ID=90059256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322257A IL322257A (he) | 2023-02-23 | 2024-02-21 | שיטות לטיפול בסרטן השד |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4669363A1 (he) |
| JP (1) | JP2026506981A (he) |
| KR (1) | KR20250149794A (he) |
| CN (1) | CN121013734A (he) |
| AU (1) | AU2024225706A1 (he) |
| IL (1) | IL322257A (he) |
| MX (1) | MX2025009867A (he) |
| TW (1) | TW202434313A (he) |
| WO (1) | WO2024176147A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025126151A1 (en) * | 2023-12-15 | 2025-06-19 | Novartis Ag | Methods for treating breast cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114728088A (zh) | 2019-09-16 | 2022-07-08 | 诺华股份有限公司 | 稳定的浓缩的放射性药物组合物 |
| TWI878344B (zh) | 2019-09-17 | 2025-04-01 | 瑞士商諾華公司 | 放射性標記grpr拮抗劑之方法及其套組 |
| WO2021171261A1 (en) | 2020-02-28 | 2021-09-02 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
-
2024
- 2024-02-21 JP JP2025548223A patent/JP2026506981A/ja active Pending
- 2024-02-21 EP EP24707939.5A patent/EP4669363A1/en active Pending
- 2024-02-21 WO PCT/IB2024/051682 patent/WO2024176147A1/en not_active Ceased
- 2024-02-21 TW TW113106189A patent/TW202434313A/zh unknown
- 2024-02-21 AU AU2024225706A patent/AU2024225706A1/en active Pending
- 2024-02-21 IL IL322257A patent/IL322257A/he unknown
- 2024-02-21 CN CN202480013734.5A patent/CN121013734A/zh active Pending
- 2024-02-21 KR KR1020257031223A patent/KR20250149794A/ko active Pending
-
2025
- 2025-08-21 MX MX2025009867A patent/MX2025009867A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250149794A (ko) | 2025-10-16 |
| JP2026506981A (ja) | 2026-02-27 |
| CN121013734A (zh) | 2025-11-25 |
| TW202434313A (zh) | 2024-09-01 |
| MX2025009867A (es) | 2025-09-02 |
| EP4669363A1 (en) | 2025-12-31 |
| WO2024176147A1 (en) | 2024-08-29 |
| AU2024225706A1 (en) | 2025-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025503451A (ja) | 炭酸脱水酵素ixリガンド | |
| TWI605815B (zh) | 用於製備包含阿米福丁與胺基酸之腎保護劑的組成物及方法 | |
| IL322257A (he) | שיטות לטיפול בסרטן השד | |
| US9180214B1 (en) | Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer | |
| JP7665726B2 (ja) | アルファ放射標識ガストリンアナログおよびcckb受容体陽性疾患の処置方法におけるその使用 | |
| IL322112A (he) | שיטות לטיפול בגליובלסטומה | |
| JP7665727B2 (ja) | 特にcckb受容体陽性の癌もしくは腫瘍の処置および/または診断に使用するための、ラパログと放射標識ガストリンアナログとを含む組成物 | |
| IL303930A (he) | אנטגוניסט רדיואקטיבי לאלפא v בטא 3 ו\או אלפא v בטא 4 אינטגרינים ושימוש שלהם בתור חומר תראגוניסטי | |
| WO2025126151A1 (en) | Methods for treating breast cancer | |
| JP2023536261A (ja) | Cckb受容体陽性腫瘍または癌の画像化方法におけるガリウム標識ガストリン類似体および使用 | |
| CA3234495A1 (en) | Combination therapy of radionuclide complex | |
| Facca | EGFR and HER2-targeted radioimmunoconjugates for theranostic molecular imaging and Auger electron radioimmunotherapy of breast cancer | |
| KR20260014588A (ko) | 전립선암의 진단 및/또는 치료 방법 | |
| WO2026088112A1 (en) | Combination therapies with ar-degrading agents and psma-targeting radioligands | |
| KR20250109190A (ko) | 암의 식별 및/또는 치료 | |
| JP2005535676A5 (he) | ||
| JP2005535676A (ja) | 腫瘍の処置における放射免疫療法の効果の増強 |